Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726711 | 1.00 | DDB1 (0.60) | DDB1CRBNGPR119MEN1CYP3A4 | |
| SCHEMBL31726780 | 0.94 | DDB1 (0.58) | DDB1CRBNGPR119 | |
| SCHEMBL29680902 | 0.94 | DDB1 (0.58) | DDB1CRBNGPR119 | |
| SCHEMBL30831066 | 0.93 | DDB1 (0.59) | DDB1CRBNGPR119CYP3A4CYP2C19 | |
| SCHEMBL26641205 | 0.93 | CRBN (0.59) | DDB1CRBNGPR119 | |
| SCHEMBL30830936 | 0.92 | DDB1 (0.52) | DDB1CRBNGPR119MEN1CYP3A4 | |
| SCHEMBL23301226 | 0.92 | DDB1 (0.67) | DDB1CRBNGPR119 | |
| SCHEMBL21876964 | 0.92 | DDB1 (0.67) | DDB1CRBNGPR119 | |
| SCHEMBL30768423 | 0.91 | CRBN (0.57) | DDB1CRBNGPR119CYP3A4CYP2C19 | |
| SCHEMBL24480733 | 0.89 | GPR119 (0.62) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024220843-A1 | TECHNOLOGIES TARGETING CELL STATES | AURON THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2022133285-A1 | MOLECULES AND METHODS RELATED TO TREATMNET OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-06-23 | — | — | WO | disclosed |